Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067737 · ClinicalTrials.gov registry record · Phase 2
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06067737 is a Phase 2 study of Opioid Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06067737, a Phase 2 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067737
The ClinicalTrials.gov registry entry for NCT06067737 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06067737 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06067737 about?
NCT06067737 is a clinical study titled "Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder". This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone b...
What is the current status of trial NCT06067737?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-02-08. Estimated completion is 2029-05.
What conditions does trial NCT06067737 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06067737?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06067737?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067737 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.